Bolt Biotherapeutics, Inc.
BOLT- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001641281
In the last 90 days, Bolt Biotherapeutics, Inc. insiders filed 3 open-market purchases and 3 sales; 23 institutions reported holding it in 13F filings for Q2 2026, worth $2.31M in total; no superinvestor holds it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Oct 8, 2026, 1:48 PM ET
Revenue flow, FY2025
Where the revenue went in FY2025, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.
Net loss for FY2025: $33.4M (433.7% of revenue).
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 12, 2026 | Mar 24, 2025 | Mar 21, 2024 | Mar 29, 2023 | Mar 30, 2022 |
| Revenue | $7.70M | $7.69M | $7.88M | $5.73M | $1.26M |
| Operating expenses | $43.8M | $80.7M | $84.1M | $96.0M | $94.0M |
| Research and development | $28.5M | $57.5M | $61.5M | $73.1M | $75.7M |
| Selling, general and administrative | $13.8M | $18.5M | $22.5M | $22.9M | $18.4M |
| Operating income | -$36.1M | -$73.0M | -$76.2M | -$90.3M | -$92.8M |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Net income | -$33.4M | -$63.1M | -$69.2M | -$88.1M | -$98.6M |
| EPS, basic | $-17.85 | $-1.65 | $-1.83 | $-2.36 | – |
| EPS, diluted | $-17.85 | $-1.65 | $-1.83 | $-2.36 | – |
| Weighted shares, basic | 1.87M | 38.2M | 37.8M | 37.4M | 33.2M |
| Weighted shares, diluted | 1.87M | 38.2M | 37.8M | 37.4M | – |
| Margins and growth | |||||
| Operating margin | -469.3% | -949.9% | -967.4% | -1576.6% | -7364.1% |
| Net margin | -433.7% | -820.8% | -878.6% | -1537.8% | -7824.7% |
| Revenue growth, year over year | +0.1% | −2.4% | +37.5% | +354.7% | – |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 12, 2026 | Mar 24, 2025 | Mar 21, 2024 | Mar 29, 2023 | Mar 30, 2022 |
| Cash and equivalents | $11.7M | $7.21M | $10.8M | $9.24M | $27.4M |
| Short-term investments | $15.8M | $40.1M | $91.4M | $159.6M | $158.8M |
| Total current assets | $30.3M | $50.8M | $105.7M | $172.7M | $189.2M |
| Property, plant and equipment | $1.25M | $3.14M | $4.96M | $6.45M | $6.16M |
| Total assets | $56.7M | $99.6M | $159.8M | $227.8M | $307.7M |
| Accounts payable | $1.44M | $1.51M | $2.99M | $3.59M | $3.57M |
| Total current liabilities | $8.44M | $15.9M | $20.5M | $23.1M | $21.3M |
| Total liabilities | $30.2M | $42.4M | $47.0M | $56.3M | $57.6M |
| Shareholders' equity | $26.5M | $57.2M | $112.7M | $171.5M | $250.1M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 12, 2026 | Mar 24, 2025 | Mar 21, 2024 | Mar 29, 2023 | Mar 30, 2022 |
| Operating cash flow | -$39.9M | -$61.3M | -$69.5M | -$76.5M | -$57.1M |
| Capital expenditures | $72.0K | $41.0K | $206.0K | $1.95M | $2.34M |
| Free cash flow | -$39.9M | -$61.3M | -$69.7M | -$78.5M | -$59.4M |
| Depreciation and amortization | $1.29M | $1.78M | $1.85M | $1.67M | $1.19M |
| Stock-based compensation | $2.78M | $7.41M | $9.22M | $9.58M | $8.50M |
| Investing cash flow | $44.3M | $57.6M | $71.0M | $57.9M | -$232.2M |
| Financing cash flow | $19.0K | $108.0K | $253.0K | $503.0K | $311.1M |
| Net change in cash | $4.47M | -$3.60M | $1.77M | -$18.1M | $21.8M |
| Ratio | |||||
| Stock-based compensation, % of revenue | 36.2% | 96.3% | 117.1% | 167.1% | 674.6% |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Aug 4, 2026 | 1.93M | +0.4% | SEC |
| May 5, 2026 | 1.92M | −95.0% | SEC |
| Mar 6, 2026 | 1.92M | −95.0% | SEC |
| Nov 5, 2025 | 1.92M | −95.0% | SEC |
| Aug 7, 2025 | 1.92M | −95.0% | SEC |
| May 5, 2025 | 38.3M | +0.6% | SEC |
| Mar 19, 2025 | 38.3M | +0.6% | SEC |
| Nov 6, 2024 | 38.3M | +0.8% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits. Stock splits since Dec 31, 2020, from 13F share counts: 1-for-20 in Q2 2025.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.